SLS Insider Trading Activity and SEC Form 4 Filings
SLS insider trading summary
Over the past 12 months, insiders at SELLAS Life Sciences Group, Inc. (SLS) reported 1 open-market purchase worth $101K by 1 insider and no sales on SEC Form 4. Net insider buying was $101K.
Latest SLS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 19, 2025 | Katherine Bach Kalin | Director | Buy | $101K (63,400 @ $1.59) |
| Jun 12, 2025 | Nostrand Robert L Van | Director | Buy | $15K (10,000 @ $1.48) |
| May 30, 2025 | Jane Wasman | Director | Buy | $34K (20,000 @ $1.69) |
| May 22, 2025 | Katherine Bach Kalin | Director | Buy | $36K (20,000 @ $1.80) |
| Dec 5, 2022 | Angelos M. Stergiou | President and CEO | Sell | $17K (6,494 @ $2.61) |
| Dec 5, 2022 | John Thomas Burns | Senior VP, Finance & CAO | Sell | $3K (1,159 @ $2.59) |
| Dec 5, 2022 | Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | Sell | $6K (2,153 @ $2.59) |
| Dec 2, 2021 | Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | Sell | $5K (847 @ $6.25) |
| Dec 2, 2021 | Angelos M. Stergiou | President and CEO | Sell | $13K (2,120 @ $6.25) |
| Dec 2, 2021 | John Thomas Burns | VP, Finance & Corp Controller | Sell | $1K (231 @ $6.27) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.